Caplin Point Laboratories has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA) for the recent inspection conducted at Caplin Steriles’ injectable and ophthalmic manufacturing facility located at Gummidipoondi. The unannounced USFDA inspection was conducted between August 5, 2024 and August 9, 2024 and was concluded with Zero 483 observations, reflecting the company's commitment to maintaining the highest standards of quality and compliance. The inspection, which is a routine part of the FDA's regulatory oversight, evaluates compliance with Good Manufacturing Practices and other regulatory requirements.
Caplin Point Laboratories is engaged mainly in manufacturing a wide range of Ointments, Creams and other External application preparations in addition to the regular segments of pharmaceutical formulations.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1837.30 |
Dr. Reddys Lab | 1370.60 |
Cipla | 1495.05 |
Lupin | 2252.40 |
Zydus Lifesciences | 981.55 |
View more.. |